Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy (ProCAID)
An Open Label Phase I/Randomised, Double Blind Phase II Study in Metastatic Castration Resistant Prostate Cancer of AZD5363 In Combination With Docetaxel and Prednisolone Chemotherapy (ProCAID)
Sponsor: AstraZeneca
This PHASE1/PHASE2 trial investigates Prostate Cancer and is currently completed. AstraZeneca leads this study, which shows 13 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Apr 2021 — Jun 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 8 earlier versions
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Sep 2019 — Dec 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Aug 2019 — Sep 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Mar 2019 — Aug 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2019 — Mar 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2018 — Feb 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Jan 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Cancer Research UK
- University Hospital Southampton NHS Foundation Trust
For direct contact, visit the study record on ClinicalTrials.gov .